Drugs That Changed the World

Total Page:16

File Type:pdf, Size:1020Kb

Drugs That Changed the World Drugs That Changed the World Drugs That Changed the World How Therapeutic Agents Shaped Our Lives Irwin W. Sherman CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed on acid-free paper Version Date: 20160922 International Standard Book Number-13: 978-1-4987-9649-1 (Hardback) This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal respon- sibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not neces- sarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies’ and device or material manufacturers’ printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material repro- duced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including pho- tocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http:// www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Names: Sherman, Irwin W., author. Title: Drugs that changed the world : how therapeutic agents shaped our lives / Irwin W. Sherman. Description: Boca Raton : Taylor & Francis, 2017. | Includes bibliographical references. Identifiers: LCCN 2016022679 | ISBN 9781498796491 (hardback : alk. paper) Subjects: | MESH: Pharmaceutical Preparations--history | Drug Therapy--history | Drug Discovery--history | Social Change--history Classification: LCC RM300 | NLM QV 11.1 | DDC 615.1--dc23 LC record available at https://lccn.loc.gov/2016022679 Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com Contents List of Figures ............................................................ .vii Preface ................................................................... ix A Note to the Reader ........................................................ xi Chapter 1 Malaria and Antimalarials .......................................... 3 Chapter 2 The Painkiller, Aspirin............................................. 31 Chapter 3 Ether, Chloroform, Cocaine, Morphine, Heroin, and Anesthesia ........... 39 Chapter 4 The Pill......................................................... 53 Chapter 5 Diabetes and Insulin.............................................. 65 Chapter 6 Smallpox and Vaccination .......................................... 75 Chapter 7 Vaccines to Combat Infectious Diseases .............................. 87 Chapter 8 The Great Pox Syphilis and Salvarsan................................ 115 Chapter 9 Prontosil, Pyrimethamine, and Penicillin ............................. 125 v vi Contents Chapter 10 AIDS, HIV, and Antiretrovirals .................................... 147 Chapter 11 Organ Transplantation and Cyclosporine ............................. 159 Chapter 12 Malaria, Madness, and Chlorpromazine ............................. 171 Epilogue ................................................................. 181 Notes ���������������������������������������������������������������������������������������������������������������������������������������185 Index ................................................................... 191 List of Figures Figure 1.1 A comparison of the structures of quinoline, acridine, methylene blue, and the derivative of methylene blue, atabrine. .......................14 Figure 1.2 A sign from the South Pacific theater of operations. ...................17 Figure 1.3 A comparison of the structure of chloroquine with quinine and atabrine. ....18 Figure 1.4 A comparison of the structure of mefloquine with quinine. 22 Figure 1.5 A comparison of the structures of artemisinin, artemether, and artesunate. ...27 Figure 2.1 Formation of acetylsalicylic acid (aspirin) by treatment of salicylic acid with acetic anhydride. ...........................................34 Figure 4.1 Russell Marker with the yam “cabeza de negro.”.......................55 Figure 4.2 A comparison of the structure of diosgenin with progesterone and norethindrone. ..............................................56 Figure 9.1 The relationship of prontosil with sulfanilamide and that of pABA. ......129 Figure 9.2 (a) The folate pathway and (b) the thymidylate cycle. ..................132 Figure 12.1 A comparison of the structure of methylene blue with phenothiazine and chlorpromazine. ...........................................176 vii Preface he dictionary defines drug as a therapeutic agent. Through the ages, drugs—natural or Tsynthetic—have been used in the diagnosis, alleviation, treatment, prevention, or cure of disease. These drugs are based on thousands of years of knowledge accumulated from folklore, serendipity, and scientific discovery. This is a book about drugs that have changed the world in which we live, how they were developed, and the manner in which they exert their “magic.” In telling the fascinating history of the findings and use of drugs, there is drama of triumphs and failures filled with colorful personalities—the selfless and the selfish, the competitor and the cooperator, the hero and the villain, those with unbridled ambition, those seeking fortune, and the bold as well as the timid. Today, there are drugs to protect against infectious diseases, to alleviate aches and pains, to allow new organs to replace old ones, and to modify brain function. Yet, for the most part, the manner by which drugs are developed and by whom remains a mystery. For many of us, a drug is a pill or a liquid, prescribed by a physician, found in the medicine cabinet. Drugs are more than this, and although only several dozen or so drugs have markedly affected our lives and altered the path of civilization, to simply catalog these would be too numbing to read. Instead, I have selected a sampling—drugs that represent milestones in affecting our well-being and that have influenced social change. Quinine, the first antimalarial to cure the disease malaria (Chapter 1), illustrates how a natu- ral product enabled armies to triumph in the tropics. This chapter also deals with synthetic anti- malarials (atabrine, chloroquine, and mefloquine) and the newest natural product, artemisinin. It provides the reader with an appreciation of what goes into drug testing, the role of animal models, the need for clinical trials, and the problems associated with drug resistance. In the sec- ond two chapters, Chapter 2—on aspirin, the first drug to treat simple pain; and Chapter 3— on anesthesia, the power of making a person insensible to surgical operation, are described. Hormones, too, are drugs; their role is illustrated in “The Pill” (Chapter 4), where a synthetic hormone analog revolutionized contraceptive choices for women; and in Chapter 5, where the isolation of insulin, the first hormone therapy for treating diabetes, is examined. Smallpox (Chapter 6) led to a vaccine that ultimately eradicated the disease and was the impetus for the development of other vaccines to combat infectious diseases (Chapter 7). Syphilis (Chapter 8) provided the spark for a cure through chemotherapy (salvarsan), which
Recommended publications
  • EMJ-5.2-2020-4.Pdf
    Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al.
    [Show full text]
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
    [Show full text]
  • 2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S
    2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S. Jordan, Jr., M.D. With a Tribute by John R. LaMontagne, Ph.D. May 25, 2004 Arlington, Virginia INTRODUCTION by H.R. Shepherd, D.Sc. Chairman, The Albert B. Sabin Vaccine Institute he Sabin Vaccine Institute pursues Dr. Albert B. Sabin’s vision of a T world protected from disease by vaccines. The annual awarding of the Sabin Gold Medal has always been among our most meaningful traditions. The 2004 award was presented in May to an icon in vaccine research, William S. Jordan, Jr., M.D., at a ceremony in Arlington, Virginia, during the 7th Annual Conference on Vaccine Research, co-organized by the Sabin Vaccine Institute. The positive impact of vaccines on the health and well being of humanity continues to be a marvel of our modern world. Vaccine improvements, new vaccines, and vaccines in the pipeline represent an advancing field of science that brings untold preventive benefit to millions around the world. Along with his career in vaccine research, Dr. Jordan has engaged in compiling the record of scientific advancements in the field. His name is synonymous with both vaccine research and the compendium—The Jordan Report—that for 25 years has been a repository for advances in the vaccine field. The Sabin Gold Medal Advisory Committee, chaired by Maj. Gen. Philip K. Russell, M.D. (USA Ret.), selected Dr. Jordan for this honor after canvassing 300 members of the scientific community. We are pleased to recognize Dr. Jordan with this honor, noting his exemplary contributions in the vaccine field and commitment to lifesaving medical discoveries.
    [Show full text]
  • Wellcome Four Year Phd Programme in Integrative Cell Mechanisms
    2021 Wellcome Four Year PhD Programme in Integrative Cell Mechanisms Training the next generation of Molecular Cell Biologists Background and Aims of Programme The Wellcome Four Year PhD Programme in Integrative Cell Mechanisms (iCM) is closely associated with the Wellcome Centre for Cell Biology and trains the next generation of cell and molecular biologists in the application of quantitative methods to understand the inner workings of distinct cell types in different settings. A detailed understanding of normal cellular function is required to investigate the molecular cause of disease and design future treatments. However, data generated by biological research requires increasingly complex analysis with technological advances in sequencing, mass spectrometry/proteomics, super-resolution microscopy, Wellcome Centre for Cell Biology 2021 synthetic and structural biology generating increasingly large, complex datasets. In addition, innovations in computer sciences and informatics are transforming data acquisition and analysis and breakthroughs in physics, chemistry and engineering allow the development of devices, molecules and instruments that drive the biological data revolution. Exploiting technological advances to transform our understanding of cellular mechanisms will require scientists who have been trained across the distinct disciplines of natural sciences, engineering, informatics and mathematics. To address this training need, iCM PhD projects are cross-disciplinary involving two primary supervisors with complementary expertise. Supervisor partnerships pair quantitative scientists with cell biologists ensuring that students develop pioneering cross-disciplinary collaborative projects to uncover cellular mechanisms relevant to health and disease. We aim to recruit students with a variety of backgrounds across the biological and physical sciences, including Biochemistry, Biomedical Science, Cell Biology, Chemistry, Computational Data Sciences, Engineering, Genetics, Mathematics, Molecular Biology and Physics.
    [Show full text]
  • Robert Purcell: Okay
    Office of NIH History Oral History Interview with Dr. Robert H. Purcell (NIAID, LID) Conducted on December 7, 2005, by Dr. Lisa K. Walker At the National Institutes of Health, Bethesda, Maryland Abstract: Dr. Purcell describes his education and training, his early career in the Laboratory of Infectious Diseases, and his work since he has headed LID studies of hepatitis viruses. He describes how the LID broadened its work, from a focus on viruses causing respiratory diseases through the early 1960s, to include hepatitis as well as gastroenteritis viruses. He also discusses internal collaborations at NIH and extramural collaborations, and many of the chance findings and coincidences that helped to further study of hepatitis and control of infection. Dr. Purcell also comments on how advances in technology and instrumentation have influenced the study of hepatitis viruses. Lisa Walker: I would like to start out by hearing a little bit about your growing up, and your family and your decisions as you entered university and training in chemistry to begin with. Robert Purcell: Okay. I was born in Iowa and moved to Texas when I was six months old, and spent my first nine years in Dallas, Texas. Then my family moved to rural Oklahoma, and that’s where I lived until I finished college and then went off to medical school. I guess I developed an interest in science from my brother, who was in college and was taking science courses, [and] who would come home with interesting little tidbits about things, and that really kind of excited me. The school I went to, since it was in rural Oklahoma, actually was a minimal school.
    [Show full text]
  • A Case Study of Glaxosmithkline Plc )
    )l GROWTH THROUGH MERGER: A CASE STUDY OF GLAXOSMITHKLINE PLC ) / BY JUNE WANGARI UNIVERSITY OF NAIR03J LOWER KABETE LIBRARY A MANAGEMENT RESEARCH PROJECT SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF DEGREE OF MASTER OF BUSINESS ADMINISTRATION (MBA), SCHOOL OF BUSINESS, UNIVERSITY OF NAIROBI JULY, 2008 DECLARATION I declare that this project is my original work and has never been presented for academic purposes in any other University. CANDIDATE: JUNE WANGARI DATE .(.91. This research project has been submitted for examination with my approval as the University Supervisor SIGNED. DATE. Prof. Evans Aosa Department Of Business Administration, School Of Business, University Of Nairobi 11 DEDICATION I dedicate this project to my daughter Jemima, who was born within the first year of my post graduate studies. And now that she is in kindergarten, I see that I have instilled in her the love for reading and learning and I trust that she will go very far. iii ACKNOWLEDGEMENT I thank God for seeing me through my studies as I tried to balance between my family, my work and my studies. I wish to acknowledge the contributions that were made in the course of this project by several individuals and organizations. I wish to acknowledge gratefully the following people, whose effort influenced the content and direction of this project. My first thanks go to my Supervisor Prof. Evans Aosa for his constant analytical criticism and encouragement. Thanks a lot. I wish to thank my friends for a lot of support and encouragement to me in pursuit of this goal.
    [Show full text]
  • MEDICINAL PLANTS OPIUM POPPY: BOTANY, TEA: CULTIVATION to of NORTH AFRICA Opidjd CHEMISTRY and CONSUMPTION by Loutfy Boulos
    hv'IERIGAN BCXtlNICAL COJNCIL -----New Act(uisition~---------l ETHNOBOTANY FLORA OF LOUISIANA Jllll!llll GUIDE TO FLOWERING FLORA Ed. by Richard E. Schultes and Siri of by Margaret Stones. 1991. Over PLANT FAMILIES von Reis. 1995. Evolution of o LOUISIANA 200 beautiful full color watercolors by Wendy Zomlefer. 1994. 130 discipline. Thirty-six chapters from and b/w illustrations. Each pointing temperate to tropical families contributors who present o tru~ accompanied by description, habitat, common to the U.S. with 158 globol perspective on the theory and and growing conditions. Hardcover, plates depicting intricate practice of todoy's ethnobotony. 220 pp. $45. #8127 of 312 species. Extensive Hardcover, 416 pp. $49.95. #8126 glossary. Hardcover, 430 pp. $55. #8128 FOLK MEDICINE MUSHROOMS: TAXOL 4t SCIENCE Ed. by Richard Steiner. 1986. POISONS AND PANACEAS AND APPLICATIONS Examines medicinal practices of by Denis Benjamin. 1995. Discusses Ed. by Matthew Suffness. 1995. TAXQL® Aztecs and Zunis. Folk medicine Folk Medicine signs, symptoms, and treatment of Covers the discovery and from Indio, Fup, Papua New Guinea, poisoning. Full color photographic development of Toxol, supp~. Science and Australia, and Africa. Active identification. Health and nutritional biology (including biosynthesis and ingredients of garlic and ginseng. aspects of different species. biopharmoceutics), chemistry From American Chemical Society Softcover, 422 pp. $34.95 . #8130 (including structure, detection and Symposium. Softcover, isolation), and clinical studies. 223 pp. $16.95. #8129 Hardcover, 426 pp. $129.95 #8142 MEDICINAL PLANTS OPIUM POPPY: BOTANY, TEA: CULTIVATION TO OF NORTH AFRICA OpiDJD CHEMISTRY AND CONSUMPTION by Loutfy Boulos. 1983. Authoritative, Poppy PHARMACOLOGY TEA Ed.
    [Show full text]
  • COLLEGE of LETTERS and SCIENCE ALUMNI: KNOWLEDGE in ACTION COLLEGE of LETTERS and SCIENCE Dear Friends and Colleagues, Dean, Nicol C
    THE COLLEGE OF LETTERS AND SCIENCE • MONTANA STATE UNIVERSITY • 2016-2017 • VOLUME 13 COLLEGE OF LETTERS AND SCIENCE ALUMNI: KNOWLEDGE IN ACTION COLLEGE OF LETTERS AND SCIENCE Dear friends and colleagues, Dean, Nicol C. Rae Associate Dean, David Cherry In 2016, Montana State University Associate Dean, Bridget Kevane celebrated and honored the legacy of Director of Finance and Administration, Mindy Brown Assistant to the Dean, Sarah Miller Maurice Hilleman, the College of Letters Administrative and Student Support Coordinator, and Science’s—and arguably MSU’s— Nicol Rae. Jennifer Storment most world-changing alumnus. Communications Director, Jody Sanford Advising Coordinator, Erica Dungan Hillman graduated from MSU in 1941 with degrees in chemistry and Accounting Operations Manager, Cassandra Balent microbiology. He pursued a career as a microbiologist, specializing in vaccinology Information Technology Director, Michael Wright and developing over 40 vaccines, an unparalleled record of productivity. Of the COLLEGE OF LETTERS AND SCIENCE 14 vaccines routinely recommended in current vaccine schedules, he developed ADVISORY COUNCIL eight: those for measles, mumps, hepatitis A, hepatitis B, chickenpox, meningitis, Michael Beehler Betsy Quammen pneumonia and Haemophilus influenzae bacteria. He also played a role in the Julianne Bye Peter Roos discovery of the cold-producing adenoviruses, the hepatitis viruses and the cancer- Ingrid Degreef Peter Sadowski Marshall Gingery Bradley Snow causing virus SV40. He is credited with saving more lives than any other medical Ariana Paliobagis Gary Stoner scientist of the 20th century. Gary Popiel William Yellowtail Jr. In April of this year, MSU held the Maurice Hilleman Vaccine Symposium, DEPARTMENTS AND DEPARTMENT HEADS featuring some of the nation’s most noted experts in vaccine.
    [Show full text]
  • Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA
    GENE SILENCING BY DOUBLE STRANDED RNA Nobel Lecture, December 8, 2006 by Andrew Z. Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA. I would like to thank the Nobel Assembly of the Karolinska Institutet for the opportunity to describe some recent work on RNA-triggered gene silencing. First a few disclaimers, however. Telling the full story of gene silencing would be a mammoth enterprise that would take me many years to write and would take you well into the night to read. So we’ll need to abbreviate the story more than a little. Second (and as you will see) we are only in the dawn of our knowledge; so consider the following to be primer... the best we could do as of December 8th, 2006. And third, please understand that the story that I am telling represents the work of several generations of biologists, chemists, and many shades in between. I’m pleased and proud that work from my labo- ratory has contributed to the field, and that this has led to my being chosen as one of the messengers to relay the story in this forum. At the same time, I hope that there will be no confusion of equating our modest contributions with those of the much grander RNAi enterprise. DOUBLE STRANDED RNA AS A BIOLOGICAL ALARM SIGNAL These disclaimers in hand, the story can now start with a biography of the first main character. Double stranded RNA is probably as old (or almost as old) as life on earth.
    [Show full text]
  • Educación Química, Vol. 1, Núm. 0
    PARA QUITARLE EL POLVO Syntex, una historia mexicana La química en la historia, para la enseñanza y su divulgación en el bachillerato Felipe León Olivares1 Resumen de no disponer de hormonas en cantidad y calidad El presente trabajo explica la importancia de las suficiente, generaba un problema ya que la produc- aportaciones de la investigación científica lograda en ción era limitada y los precios muy elevados, en gran México en el campo de la Química por Syntex, medida por los procesos complejos con rendimien- donde se realizó una verdadera revolución mundial tos bajos que usaban las compañías europeas. A en la síntesis orgánica de las hormonas esteroides. pesar de esta situación, mantenían el control tecno- De esta manera, se considera importante su divulga- lógico dominando el mercado internacional de estos ción en el bachillerato, como una experiencia que productos. Por su parte, las sucursales europeas en proyecta interés al estudio de la química a las nuevas Estados Unidos tuvieron un especial éxito comercial generaciones de estudiantes. motivando a éstas a una mayor actividad de investi- gación. Por ejemplo, la Upjohn y la Parke-Davis, Introducción fomentaron una extensa investigación a través de un El presente estudio plantea la alternativa de la divul- programa de becas. Así fue que el químico Russell gación de las aportaciones de la investigación cien- E. Marker, de la Universidad Estatal de Pennsylva- tífica realizada en México en el campo de la Quími- nia, inició sus estudios sobre las hormonas esteroides ca. Ejemplos como el de ‘‘Andrés Manuel del Río’’ (Lehmann, et al., 1973:196). (Carrera, 1956:5), ‘‘Vicente Ortigosa’’ (Chamizo, Marker planteó que el punto clave en la indus- 1999:138), y el de la empresa ‘‘Hojalata y Lámina de tria de las hormonas esteroides estaba en la materia Monterrey’’ (Garritz, 1993:36), entre otros aconteci- prima; con esta hipótesis prestó atención a las plantas mientos dignos de mención, deben ser conocidos como fuente barata y abundante de hormonas.
    [Show full text]
  • Blunted Endogenous Opioid Release Following an Oral Dexamphetamine Challenge in Abstinent Alcohol- Dependent Individuals
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Turton, S., Myers, J. F. M., Mick, I., Colasanti, A., Venkataraman, A., Durant, C., ... Lingford-Hughes, A. (2018). Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol- dependent individuals. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0107-4 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1038/s41380-018-0107-4 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Nature Publishing Group at https://www.nature.com/articles/s41380-018-0107-4 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Molecular Psychiatry https://doi.org/10.1038/s41380-018-0107-4 ARTICLE Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals 1 1 1,2 3,4 1 1 Samuel Turton ● James FM Myers ● Inge Mick ● Alessandro Colasanti ● Ashwin Venkataraman ● Claire Durant ● 5 6 6 7 8,9 8,10 Adam Waldman ● Alan Brailsford ● Mark C Parkin ● Gemma Dawe ● Eugenii A Rabiner ● Roger N Gunn ● 11 1 1 Stafford L Lightman ● David J Nutt ● Anne Lingford-Hughes Received: 21 September 2017 / Revised: 9 May 2018 / Accepted: 14 May 2018 © The Author(s) 2018.
    [Show full text]
  • July 16-31, 2009
    Eagleville Times Also serving Arrington, College Grove, Rockvale, Triune & Unionville Volume 7, Issue 14 - 50¢ July 16 - 31, 2009 Eagleville, Tennessee Highway 99 THOMAS MAUPIN Improvement Project 2009 Uncle Dave Macon INSIDE Trailblazer Award Winner Ahead Of Schedule BY BOBBIE SUE SHELTON-LONAS BY MELISSA BUCHANAN Thomas Maupin, of Murfreesboro, was Page 2 Business The Highway 99 Improvement Project honored as the recipient of the 2009 Uncle Directory enters its final phase of construction ahead Dave Macon Trailblazer Award presented on of schedule, according to Jaime Fitzpatrick, the opening night of the 32nd annual festival TDOT’s Project Supervisor over the in Murfreesboro. This distinguished award is Murfreesboro Construction office. given to those who have been at the forefront Page 3 A Message of preserving a traditional art. Thomas, a six- The Highway 99 Improvement Project will From Your time buck dancing national champion is very provide drivers with added safety, widening deserving of this award. Considered one of Mayor the roadway, eliminating dangerous curves, the best flat-foot dancers in the country, he and adding 8-foot shoulders, as drivers has the awards to prove it. Winning more than who commute between Eagleville and the 60 first-place honors as well as the Nashville Concord area of Rockvale have already put Page 14 Health & Silver Stars Talent show for artists 60 years portions of the new state route to use. Wellness and older is quite of an accomplishment for The current phase of construction is the this self-taught dancer. This year he also was new roadbed that begins at Swamp Road, a finalist for the Tennessee Governor’s Award bypassing the downtown Eagleville area by in the Arts.
    [Show full text]